Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Sharh maqola

The molecular biology and therapeutic potential of Nrf2 in leukemia

Atefeh KhodakaramiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranSara AdibfarDepartment of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, IranVahid KarpishehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranShiva AbolhasaniImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranPooya JalaliImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranHamed MohammadiNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, IranJamshid Gholizadeh NavashenaqNoncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, IranMohammad Hojjat‐FarsangiBioclinicum, Department of Oncology-Pathology, Karolinska Institute, Stockholm, SwedenFarhad Jadidi-NiaraghDepartment of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. [email protected]
2022en
ABI

Annotatsiya

NF-E2-related factor 2 (Nrf2) transcription factor has contradictory roles in cancer, which can act as a tumor suppressor or a proto-oncogene in different cell conditions (depending on the cell type and the conditions of the cell environment). Nrf2 pathway regulates several cellular processes, including signaling, energy metabolism, autophagy, inflammation, redox homeostasis, and antioxidant regulation. As a result, it plays a crucial role in cell survival. Conversely, Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies, so we want to elucidate the role of Nrf2 in cancer and the positive point of its targeting. Also, in the past few years, many studies have shown that Nrf2 protects cancer cells, especially leukemic cells, from the effects of chemotherapeutic drugs. The present paper summarizes these studies to scrutinize whether targeting Nrf2 combined with chemotherapy would be a therapeutic approach for leukemia treatment. Also, we discussed how Nrf2 and NF-κB work together to control the cellular redox pathway. The role of these two factors in inflammation (antagonistic) and leukemia (synergistic) is also summarized.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

4 ta iqtibos0 ta foydalanilgan manba